What we do Fabtech Technologies Ltd provides turnkey engineering solutions for pharmaceutical manufacturing infrastructure, including design, engineering, procurement, installation, and testing of specialized pharma equipment. |
Founded in 2,018 |
Market share Fabtech is a prominent player in pharmaceutical capex engineering with international projects across Middle East, Africa and associate presence in India. |
Problem solved Solves complex medicament manufacturing infrastructure challenges, enabling regulatory compliance, facility setup, and process optimization for pharma and biotech firms. |
Top clients or who we serve Serves pharmaceutical manufacturers, biotech companies, and government healthcare entities primarily in GCC, Middle East, Africa, and India (B2B). |
Key management Hemant Mohan Anavkar, Executive Director; experienced leadership steering technical and expansion efforts. |
Our journey and innovations Started in 2018; acquired multiple firms to expand manufacturing capabilities; established subsidiaries in UAE and Middle East; launched IPO in 2025. |
Where we operate India, United Arab Emirates, Saudi Arabia, Algeria, Bangladesh, Middle East, Africa and export markets. |
Top products or what we offer End-to-end pharma plant engineering: process equipment, cleanroom HVAC, water systems, isolators, tablet compression, and packaging infrastructure. |
Top brands - |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue is project-based, cyclically aligned with pharma capex investments and regulatory-driven infrastructure upgrades. |
Our industry position Early mover in pharma infrastructure with a growing international footprint and reference projects in biosimilars, oncology, and vaccines. |
Financial highlights FY25 Revenue ₹326.67 Cr; Net Profit ₹46.45 Cr; steady revenue from high-value turnkey pharma infrastructure projects. |
Geographical revenue split - |
Order book Confirmed orders of approximately ₹926 Cr as of January 2026, with improved project conversion rates post-European acquisition. |
Whats driving growth Medicinal sovereignty policies in GCC, Middle East, and Africa; pharma infrastructure build-out over 15 years; domestic manufacturing push. |
Our future plans Expand local presence in Middle Eastern markets; consolidate manufacturing capabilities via acquisitions; leverage policy tailwinds for growth. |
Our green promise - |
Our people and values - |
Key challenges ahead Execution risks in large capex projects; geopolitical uncertainties in key markets; need to maintain technical leadership and compliance. |
Interesting facts Completed landmark projects such as first Egyptian flu vaccine plant and largest IV solutions facility in Saudi Arabia. |
Risks and strategy Mitigates project execution risks through in-house manufacturing, technical depth, and diversified geographic footprint; growth aligned with evolving pharma policies. |
